EXHIBIT 99.1
[aethlon LOGO HERE]
FOR IMMEDIATE RELEASE: Contact:
Xxxx Xxxxxxxxxx
Senior Director, Communications
858.459.7800 x302
xxxxxxxxxxx@xxxxxxxxxxxxxx.xxx
Xxxxx Xxxxxxx
Senior Director, Investor Relations
000-000-0000
xxxxxxxx@xxxxxxxxxxxxxx.xxx
AETHLON MEDICAL EXECUTES $8.4 MILLION
COMMON STOCK PURCHASE AGREEMENT
FOR IMMEDIATE RELEASE:
San Diego, CA, March 22, 2007 -Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in
developing therapeutic devices for infectious disease, today announced it has
entered into a $8.4 million Common Stock Purchase Agreement with Fusion Capital
Fund II, LLC, a Chicago-based institutional investor. Under the agreement, the
Company has agreed to sell to Fusion Capital $400,000 of its common stock on the
date that a registration statement related to the transaction is filed with the
Securities and Exchange Commission (SEC). The Company may sell an additional
$8.0 million of common stock to Fusion Capital from time to time over a 25-month
period after the SEC has declared effective the registration statement related
to the transaction. The proceeds will be used to advance the commercialization
of Aethlon's Hemopurifier(R) treatment technology.
Under the agreement, the Company has the right to sell shares of common stock to
Fusion Capital from time to time in amounts between $32,000 and $1,000,000,
depending on certain conditions, for up to $8.0 million of additional funds. The
purchase price of the shares will be based on the prevailing market prices of
the Company's shares at the time of sales without any fixed discount, and the
Company will control the timing and amount of any sales of shares to Fusion
Capital. Fusion Capital has agreed not to engage in any direct or indirect short
selling or hedging of the common stock in any manner whatsoever. A more detailed
description of the transaction, as well as copies of the material agreements, is
set forth in the Company's Form 8-K filed today with the SEC.
"We are pleased to renew our long standing relationship with Fusion Capital,"
commented Xxxxx X. Xxxxx, Aethlon Chairman and CEO. "The agreement provides us
with reasonable terms, fundraising flexibility, and the ability to sell our
shares to Fusion Capital when we determine the share price is most advantageous
for the Company," concluded Xxxxx.
ABOUT AETHLON MEDICAL
Aethlon Medical has developed a first-in-class medical device to assist in the
treatment of infectious disease. The device, known as the Hemopurifier(R), is
positioned to be a broad-spectrum treatment for drug and vaccine resistant
bioweapons, naturally evolving pandemic threats, and chronic infectious disease
targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
On March 6, 2007, Xxxxxxx submitted an Investigational Device Exemption (IDE) to
the U.S. Food and Drug Administration (FDA) requesting permission to initiate
human safety studies of the Aethlon Hemopurifier(R) as a treatment
countermeasure against select category "A" bioterror threats. Additional studies
to demonstrate utility of the Hemopurifier(R) as a countermeasure against
bioterror threats are being conducted with researchers at The Centers for
Disease Control and Prevention (CDC), The United States Army Medical Research
Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for
2
Biomedical Research (SFBR). Category "A" bioterror threats are defined by the
CDC as agents that pose a risk to national security; are easily disseminated or
transmitted from person to person; result in high mortality rates; may cause
public panic and social disruption, and require special action for public health
preparedness. Global researcher, Xxxxx & Xxxxxxxx awarded the Hemopurifier(R)
the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon
with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has
also initiated research on a second generation Hemopurifier(R) that targets the
capture of growth factors inherent in the spread of Cancer. More information on
Aethlon Medical and the HemopurifierTM technology can be found at
XXX.XXXXXXXXXXXXXX.XXX.
CERTAIN OF THE STATEMENTS HEREIN MAY BE FORWARD-LOOKING AND INVOLVE RISKS AND
UNCERTAINTIES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE ASSUMPTIONS, KNOWN AND
UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL
RESULTS, PERFORMANCE OR ACHIEVEMENTS OF AETHLON MEDICAL, INC TO BE MATERIALLY
DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY THE FORWARD-LOOKING STATEMENTS. SUCH POTENTIAL RISKS AND
UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE COMPANY'S ABILITY TO RAISE
CAPITAL WHEN NEEDED, THE COMPANY'S ABILITY TO COMPLETE THE DEVELOPMENT OF ITS
PLANNED PRODUCTS, THE ABILITY OF THE COMPANY TO OBTAIN FDA AND OTHER REGULATORY
APPROVALS PERMITTING THE SALE OF ITS PRODUCTS, THE COMPANY'S ABILITY TO
MANUFACTURE ITS PRODUCTS AND PROVIDE ITS SERVICES, THE IMPACT OF GOVERNMENT
REGULATIONS, PATENT PROTECTION ON THE COMPANY'S PROPRIETARY TECHNOLOGY, PRODUCT
LIABILITY EXPOSURE, UNCERTAINTY OF MARKET ACCEPTANCE, COMPETITION, TECHNOLOGICAL
CHANGE, AND OTHER RISK FACTORS. IN SUCH INSTANCES, ACTUAL RESULTS COULD DIFFER
MATERIALLY AS A RESULT OF A VARIETY OF FACTORS, INCLUDING THE RISKS ASSOCIATED
WITH THE EFFECT OF CHANGING ECONOMIC CONDITIONS AND OTHER RISK FACTORS DETAILED
IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION FILINGS.
3
